232 related articles for article (PubMed ID: 10625337)
21. Regulation of Schwann cell proliferation and apoptosis in PMP22-deficient mice and mouse models of Charcot-Marie-Tooth disease type 1A.
Sancho S; Young P; Suter U
Brain; 2001 Nov; 124(Pt 11):2177-87. PubMed ID: 11673320
[TBL] [Abstract][Full Text] [Related]
22. Molecular alterations resulting from frameshift mutations in peripheral myelin protein 22: implications for neuropathy severity.
Johnson JS; Roux KJ; Fletcher BS; Fortun J; Notterpek L
J Neurosci Res; 2005 Dec; 82(6):743-52. PubMed ID: 16273544
[TBL] [Abstract][Full Text] [Related]
23. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
Lee JS; Lee JY; Song DW; Bae HS; Doo HM; Yu HS; Lee KJ; Kim HK; Hwang H; Kwak G; Kim D; Kim S; Hong YB; Lee JM; Choi BO
Nucleic Acids Res; 2020 Jan; 48(1):130-140. PubMed ID: 31713617
[TBL] [Abstract][Full Text] [Related]
24. Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs.
Hanemann CO; Gabreëls-Festen AA; Stoll G; Müller HW
Acta Neuropathol; 1997 Oct; 94(4):310-5. PubMed ID: 9341930
[TBL] [Abstract][Full Text] [Related]
25. The PMP22 gene and its related diseases.
Li J; Parker B; Martyn C; Natarajan C; Guo J
Mol Neurobiol; 2013 Apr; 47(2):673-98. PubMed ID: 23224996
[TBL] [Abstract][Full Text] [Related]
26. Role of immune cells in animal models for inherited peripheral neuropathies.
Wang Ip C; Kroner A; Fischer S; Berghoff M; Kobsar I; Mäurer M; Martini R
Neuromolecular Med; 2006; 8(1-2):175-90. PubMed ID: 16775375
[TBL] [Abstract][Full Text] [Related]
27. PMP22 overexpression causes dysmyelination in mice.
Robaglia-Schlupp A; Pizant J; Norreel JC; Passage E; Sabéran-Djoneidi D; Ansaldi JL; Vinay L; Figarella-Branger D; Lévy N; Clarac F; Cau P; Pellissier JF; Fontés M
Brain; 2002 Oct; 125(Pt 10):2213-21. PubMed ID: 12244079
[TBL] [Abstract][Full Text] [Related]
28. PMP22 related congenital hypomyelination neuropathy.
Fabrizi GM; Simonati A; Taioli F; Cavallaro T; Ferrarini M; Rigatelli F; Pini A; Mostacciuolo ML; Rizzuto N
J Neurol Neurosurg Psychiatry; 2001 Jan; 70(1):123-6. PubMed ID: 11118262
[TBL] [Abstract][Full Text] [Related]
29. Myelin uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a point mutation of peripheral myelin protein-22.
Fabrizi GM; Cavallaro T; Taioli F; Orrico D; Morbin M; Simonati A; Rizzuto N
Neurology; 1999 Sep; 53(4):846-51. PubMed ID: 10489052
[TBL] [Abstract][Full Text] [Related]
30. Distinct disease mechanisms in peripheral neuropathies due to altered peripheral myelin protein 22 gene dosage or a Pmp22 point mutation.
Giambonini-Brugnoli G; Buchstaller J; Sommer L; Suter U; Mantei N
Neurobiol Dis; 2005 Apr; 18(3):656-68. PubMed ID: 15755691
[TBL] [Abstract][Full Text] [Related]
31. Schwann cells ER-associated degradation contributes to myelin maintenance in adult nerves and limits demyelination in CMT1B mice.
Volpi VG; Ferri C; Fregno I; Del Carro U; Bianchi F; Scapin C; Pettinato E; Solda T; Feltri ML; Molinari M; Wrabetz L; D'Antonio M
PLoS Genet; 2019 Apr; 15(4):e1008069. PubMed ID: 30995221
[TBL] [Abstract][Full Text] [Related]
32. Identification of the regulatory region of the peripheral myelin protein 22 (PMP22) gene that directs temporal and spatial expression in development and regeneration of peripheral nerves.
Maier M; Berger P; Nave KA; Suter U
Mol Cell Neurosci; 2002 May; 20(1):93-109. PubMed ID: 12056842
[TBL] [Abstract][Full Text] [Related]
33. Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model.
Intisar A; Woo H; Kang HG; Kim WH; Shin HY; Kim MY; Kim YS; Mo YJ; Lee YI; Kim MS
Biosens Bioelectron; 2023 Mar; 224():115055. PubMed ID: 36630746
[TBL] [Abstract][Full Text] [Related]
34. Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression.
Fortun J; Go JC; Li J; Amici SA; Dunn WA; Notterpek L
Neurobiol Dis; 2006 Apr; 22(1):153-64. PubMed ID: 16326107
[TBL] [Abstract][Full Text] [Related]
35. Many facets of the peripheral myelin protein PMP22 in myelination and disease.
Naef R; Suter U
Microsc Res Tech; 1998 Jun; 41(5):359-71. PubMed ID: 9672419
[TBL] [Abstract][Full Text] [Related]
36. Clinical and Molecular Characterization of PMP22 point mutations in Taiwanese patients with Inherited Neuropathy.
Liao YC; Tsai PC; Lin TS; Hsiao CT; Chao NC; Lin KP; Lee YC
Sci Rep; 2017 Nov; 7(1):15363. PubMed ID: 29127354
[TBL] [Abstract][Full Text] [Related]
37. Sustained Expression of Negative Regulators of Myelination Protects Schwann Cells from Dysmyelination in a Charcot-Marie-Tooth 1B Mouse Model.
Florio F; Ferri C; Scapin C; Feltri ML; Wrabetz L; D'Antonio M
J Neurosci; 2018 May; 38(18):4275-4287. PubMed ID: 29610440
[TBL] [Abstract][Full Text] [Related]
38. A transgenic rat model of Charcot-Marie-Tooth disease.
Sereda M; Griffiths I; Pühlhofer A; Stewart H; Rossner MJ; Zimmerman F; Magyar JP; Schneider A; Hund E; Meinck HM; Suter U; Nave KA
Neuron; 1996 May; 16(5):1049-60. PubMed ID: 8630243
[TBL] [Abstract][Full Text] [Related]
39. Targeting the colony stimulating factor 1 receptor alleviates two forms of Charcot-Marie-Tooth disease in mice.
Klein D; Patzkó Á; Schreiber D; van Hauwermeiren A; Baier M; Groh J; West BL; Martini R
Brain; 2015 Nov; 138(Pt 11):3193-205. PubMed ID: 26297559
[TBL] [Abstract][Full Text] [Related]
40. Rer1 and calnexin regulate endoplasmic reticulum retention of a peripheral myelin protein 22 mutant that causes type 1A Charcot-Marie-Tooth disease.
Hara T; Hashimoto Y; Akuzawa T; Hirai R; Kobayashi H; Sato K
Sci Rep; 2014 Nov; 4():6992. PubMed ID: 25385046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
